Heel debuts allergy relief and alertness products
ALBUQUERQUE, NM — Heel Inc., a homeopathic pharmaceutical company, announced the debut of ClearLife allergy relief and WellMind calming and alertness aid brands.
The ClearLife line melds three of the company’s allergy relief products under a single brand: ClearLife Nasal Spray (previously sold as Luffeel), ClearLife Tablets (previously sold as Adrisin) and ClearLife Eye Drops (previously sold as Oculoheel). The new packaging includes green branding and comes with a manufacturer’s suggested retail price of $11.99.
“With allergy season right around the corner, families can depend on ClearLife products to alleviate pesky allergy symptoms like congestion, runny nose and itchy, watery eyes,” said Cliff Clive, CEO of Heel Inc. “We’re also pleased to announce the latest addition to our impressive portfolio of homeopathic treatments — the WellMind product line. Heel is proud to offer consumers affordable and effective symptomatic relief without the common side effects of some over-the-counter medicines.”
The WellMind line includes WellMind Alertness, a new product formulated with natural ingredients to help restore mental focus and mental clarity. WellMind Calming — previously sold as Neurexan — provides temporary relief for minor, occasional nervous tension and irritability.
ERSP refers Natures Flava to FTC, FDA regarding diabetes supplement advertising
NEW YORK — The Electronic Retailing Self-Regulation Program on Tuesday announced it will refer direct response advertising for Dinamo to the Federal Trade Commission and the Food and Drug Administration after the marketer, Natures Flava, failed to respond to an ERSP inquiry.
Claims at issue in the initial inquiry included: “Diabetes no more!”; “Dinamo helps lower blood sugar levels”; and “When I woke up in the morning prior to the Dinamo, my insulin levels were usually in the high 200s – 250, 260, 270. And since I started using the Dinamo, that number has gone to about the 160s, 170s, 180s.”
Pursuant to the ERSP Policies and Procedures, after failing to provide a substantive response to ERSP’s original inquiry within 15 calendar days, the marketer was afforded a second 10-day period in which to submit a substantive response. The marketer again did not submit a written response to the inquiry and pursuant to section 2.6 (B) of the ERSP Policies and Procedures, this matter has been referred to the FTC and FDA.
ERSP is an investigative unit of the advertising industry’s system of self-regulation and is administered by the Council of Better Business Bureaus. The marketer’s advertising came to ERSP’s attention pursuant to its ongoing monitoring program.
ERSP advises Progenum International to modify advertising on weight-loss patch
NEW YORK — The Electronic Retailing Self-Regulation Program on Tuesday recommended Progenum International modify or discontinue certain claims for Zvelt, its weight-loss patch.
ERSP reviewed broadcast and online advertising for Zvelt and identified several claims for review, including: “Just apply and say goodbye to those stubborn pounds;” “Just stick the patch on and watch the pounds roll off;” and “Zvelt’s unique formula of clinically proven ingredients are absorbed slowly through the skin to stimulate your body’s natural fat burning capabilities.”
During the course of the inquiry, the marketer informed ERSP that it had voluntarily discontinued its broadcast advertising, which contained several of the claims at issue in the inquiry.
After reviewing the evidence submitted by the marketer, ERSP determined that the consumer testimonials that appear on the product website are atypical and are not supported. ERSP recommended that testimonial claims of specific weight loss include a clear and conspicuous disclosure that the weight loss was obtained in conjunction with diet and exercise.
ERSP also found that the claim “No Crazy Diets,” in the context in which it is presented, may be reasonably interpreted by consumers as meaning they can lose significant weight without the assistance of a calorie-restricted diet. ERSP concluded that this message was not accurate.
The company, in its marketer’s statement, said “Progenum appreciates all of the interaction ERSP has afforded us during this process. Their input has been extremely helpful, and in fact, has provided the basis for the new scripting we are currently developing.”
ERSP is an investigative unit of the advertising industry’s system of self-regulation and is administered by the Council of Better Business Bureaus. The marketer’s advertising came to the attention of ERSP pursuant to its ongoing monitoring program.